Prevalence of anemia in heart failure and its effects on prognosis

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 2, 2009, Pages 131-138

  Belziti, César A ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Anemia; Epidemiology; Heart failure; Hemoglobin; Mortality prevalence

Indexed keywords

FOLIC ACID; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; HEART FAILURE; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; KIDNEY FAILURE; MORTALITY; PATHOGENESIS; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; COMORBIDITY; METABOLISM; REVIEW;

ANEMIA; COMORBIDITY; HEART FAILURE; HEMOGLOBINS; HUMANS; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 64749104006     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.2.131     Document Type: Article

References (75)

1. Rosamond W, Flegal K, Furie K et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 17(4), e25-e146 (2008).
2. Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297(17), 1883-1891 (2007).
3. Gheorghiade M, Konstam.MA, Burnett JC Jr et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297(12), 1332-1343 (2007).
4. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (15), 1900-1905 (2005).
5. Nieminen M, Böhm M, Cowie M et al.; ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26(4), 384-416 (2005).
6. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46(6), e1-e82 (2005).
7. O'Meara E, Clayton T, McEntegart MB. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure. Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 113, 986-994 (2006).
8. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur. Heart J. 26(1), 11-17 (2004).
9. Bauer C, Kurtz A. Oxygen sensing in the kidney and its relation to erythropoietin production Annu. Rev. Physiol. 51, 845-856 (1989).
10. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur. Heart J. 26, 2232-2237 (2005).
11. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-α and mortality in heart failure: a community study. Circulation 118(6), 625-631 (2008).
12. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J. Interferon Cytokine Res. 18, 555-559 (1998).
13. Iversen PO, Woldbaek PR, Tonnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R166-R172 (2002).
14. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093 (2004).
15. Weiss G, Goodnough LT. Anemia of chronic disease. N. Engl. J. Med. 352, 1011-1023 (2005).
16. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res. 73(2), 298-309 (2007).
17. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 107, 223-225 (2003).
18. de Silva R, Rigby AS, Witte KK et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am. J. Cardiol. 98, 391-398 (2006).
19. Nanas JN, Matsouka C, Karageorgopoulos D et al. Etiology of anemia in patients with advanced heart failure. J. Am. Coll. Cardiol. 48, 2485-2489 (2006).
20. Silverberg DS, Wexler D, Iaiana A, Schartz D. The interaction between heart failure and other diseases, renal failure and anemia. Semin. Nephrol. 26(4), 296-306 (2006).
21. Androne AS, Katz SD, Lund L. Hemodilution is common in patients with advanced heart failure. Circulation 107, 226-229 (2003).
22. Fyhrquist F, Karpinnen K, Honkanen T, Saijonmaa O, Rosenlof K. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J. Intern. Med. 226, 257-260 (1989).
23. Ishani A, Weinhandl E, Zhao Z et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 45, 391-399 (2005).
24. McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev. Cardiovasc. Med. 6(Suppl. 3), S4-S12 (2005).
25. McCullough PA, Lepor NE. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev. Cardiovasc. Med. 6(1), 1-10 (2005).
26. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113(20), 2454-2461 (2006).
27. Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J. Card. Fail. 10(1 Suppl.), S1-S4 (2004).
28. Tang Y-D, Katz SD. The prevalence of anemia in chronic heart failure and its impact on clinical outcomes. Heart Fail. Rev. 13, 387-383 (2008).
29. Anand IS. Anemia and chonic heart failure. Implications and treatment options. J. Am. Coll. Cardiol. 52(7), 501-511 (2008).
30. IV. NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am. J. Kidney Dis. 37, S182-S238 (2001).
31. Maggioni AP, Opasich C, Anand IS et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J. Card. Fail. 11(2), 91-98 (2005).
32. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110(2), 149-154 (2004).
33. Kalra PR, Collier T, Cowie MR et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362, 211-212 (2003).
34. Berry C, Norrie J, Hogg K, Brett M, Stevenson K, Mc Murray JJ. The prevalence, nature, and importance of hematological abnormalities in heart failure. Am. Heart J. 151, 1313-1321 (2006).
35. Anand IS, Kuskowsky MA, Rector T et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112(8), 1121-1127 (2005).
36. Levy WC. Anemia in heart failure. Marker or mediator of adverse prognosis? J. Am. Coll. Cardiol. 51, 577-578 (2008).
37. Tang WHW, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol. 51, 569-576 (2008).
38. Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 91, 907-913 (2005).
39. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Anemia and heart failure: a community study. Am. J. Cardiol. 121(8), 726-732 (2008).
40. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br. Heart J. 70, 357-362 (1993).
41. Sarnak MJ, Tighiouart H, Manjunath G et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J. Am. Coll. Cardiol. 40, 27-33 (2002).
42. Zakai NA, Katz R, Hirsch C et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort. The cardiovascular health study. Arch. Intern. Med. 165, 2214-2220 (2005).
43. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. Suppl. 87, S6-S11 (2003).
44. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 65(5), 1864-1869 (2004).
45. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am. J. Med. 116(Suppl. 7A), S27-S43 (2004).
46. Goodnough LT, Nissenson AR. Anemia and its clinical consequences in patients with chronic diseases. Am. J. Med. 116(Suppl. 7A), S1-S2 (2004).
47. Sabatine MS, Morrow DA, Giugliano RP et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111, 2042-2049 (2005).
48. Kulier A, Levin J, Moser R et al.; Investigators of the Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 116, 471-479 (2007).
49. Reinecke H, Trey T, Wellmann J et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur. Heart J. 24, 2142-2150 (2003).
50. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significants increase in mortality in patients with advanced heart failure. J. Am. Coll. Cardiol. 39, 1780-1786 (2002).
51. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur. Heart J. 25(12), 1021-1028 (2004).
52. Szachniewicz J, Petruk-Kowalczyk J, Magda J et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int. J. Cardiol. 90(2-3), 303-308 (2003).
53. Kosiborod M, Curtis JP, Wang Y et al. Anemia and outcomes in patients with heart failure. A Study From the National Heart Care Project. Arch. Intern. Med. 165, 2237-2244 (2005).
54. Formiga F, Chivite D, Castaner O, Manito N, Ramon JM, Pujol R. Anemia in new-onset congestive heart failure inpatienls admitted for acute decompensation. Eur. J. Intern. Med. 17, 179-184 (2006).
55. Groenveld HF, Januzzi JL. Damman K et al. Anemia and mortality in heart failure patients. A systematic review and meta-analysis. J. Am. Coll. Cardiol. 52, 818-827 (2008).
56. Mozaffarian D, Nye R, WC Levy. Anemia predicts mortality in severe heart failure. The Prospective Randomized Amlodipine Survival Evaluation (PRAISE). J. Am. Coll. Cardiol. 41, 1933-1939 (2003).
57. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998).
58. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355(20), 2085-2098 (2006).
59. Komajda M, Anker SD, Charlesworth A et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur. Heart J. 27(12), 1440-1446 (2006).
60. de Denus S, Tardif JC, White M et al. Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring - further insights from SOLVD. Can. J. Cardiol. 24(1), 45-48 (2008).
61. Vincent JL, Baron JF, Reinhart K et al. Anemia and blood transfusion in critically ill patients. JAMA 288, 1499-1507 (2002).
62. Bolger AP, Bartlett FR, Penston HS et al. Intravenous iron aJone for the treatment of anemia in patients with chronic heart failure. J. Am. Coll. Cardiol. 48, 1225-1227 (2006).
63. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J. Am. Coll. Cardiol. 50, 1657-1665 (2007).
64. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic-heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 51, 103-112 (2008).
65. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J. Card. Fail. 13(1), 14-17 (2007).
66. Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35, 1737-1744 (2000).
67. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37, 1775-1780 (2001).
68. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107, 294-299 (2003).
69. Palazzuoli A, Silverberg DS, Iovine F et al. Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am. Heart J. 154, 645 e9-e15 (2007).
70. Ponikowski P, Anker SD, Szachniewicz J et al. Effect of darbepoetin α on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 49, 753-762 (2007).
71. van Veldhuisen DJ, Dickstein K, Cohen-Solal A et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur. Heart J. 28, 2208-2216 (2007).
72. Ghali JK, Anand IS, Abraham WT et al. Randomized double-blind trial of darbepoetin α in patients with symptomatic heart failure and anemia. Circulation 117, 526-535 (2008).
73. Mix TC, Brenner RM, Cooper ME et al. Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am. Heart J. 149(3), 408-413 (2005).
74. van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur. J. Heart Fail. 9, 110-112 (2007).
75. Howlett JG. Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction. Expert Rev. Cardiovasc. Ther. 6(2), 199-208 (2008).